Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
Article first published online: 4 SEP 2006
Clinical & Experimental Allergy
Volume 36, Issue 9, pages 1115–1121, September 2006
How to Cite
Berth-Jones, J., Arkwright, P. D., Marasovic, D., Savani, N., Aldridge, C. R., Leech, S. N., Morgan, C., Clark, S. M., Ogilvie, S., Chopra, S., Harper, J. I., Smith, C. H., Rook, G. A. W. and Friedmann, P.S. (2006), Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clinical & Experimental Allergy, 36: 1115–1121. doi: 10.1111/j.1365-2222.2006.02558.x
- Issue published online: 4 SEP 2006
- Article first published online: 4 SEP 2006
- Submitted 09 April 2006; revised 10 June 2006; accepted 06 July 2006
- atopic dermatitis;
- double blind;
- hygiene hypothesis;
- Mycobacterium vaccae;
- placebo-controlled trial;
- SASSAD score
Background The hygiene hypothesis is often proposed to explain the high prevalence of atopy in the western world. Dysregulation of the immune system may result from inadequate exposure to micro-organisms such as mycobacteria. A small trial suggested that a killed extract of Mycobacterium vaccae ameliorates atopic dermatitis (AD).
Objectives To confirm in a large clinical trial whether killed M. vaccae ameliorates AD in 5–16-year-old children.
Methods This was a randomized, placebo-controlled, double-blind, multi-centre study of the effect of intradermal injection of killed M. vaccae (0.1 or 1 mg) on patients, aged 5–16, with moderate-to-severe AD. Patients were followed up for 24 weeks. The primary end point was the change in severity of AD at 12 weeks, assessed using the six area, six-sign, atopic dermatitis (SASSAD) score. Secondary end points included changes in disease extent, patient's global assessment and children's dermatology life quality index.
Results There were 166 patients randomized. The mean SASSAD score fell to a similar degree at week 12 in all treatment arms: from 33 to 24, (26%) in the high-dose group, from 30 to 23 (25%) in the low-dose group and from 36 to 27 (24%) in the placebo group (P>0.05). Secondary end points followed the same trend. Adverse events were generally those expected to occur in this population. Injection site reactions occurred in 32 patients at week 4.
Conclusions M. vaccae was no more effective than the placebo in ameliorating the severity of AD.